Hologic, Inc. HOLX | NASDAQ
Company Overview:
10 Year Performance Metrics:
Unlock All Reports & Research Dividend Stocks like a BOSS!
HOLX Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for HOLX
Based on past 10-year performance, here are HOLX growth metrics:
Share price CAGR of +5.35%
Dividend CAGR of +0%
Using HOLX CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| HOLX (DRIP) | HOLX - No DRIP | |
|---|---|---|
| Current Price | $57.28 | $57.28 |
| Start Shares | 174.58 | 174.58 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 174.58 | 174.58 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $91.57 | $57.28 |
| Total Dividends | $0 | $0 |
| Final Value | $15,987 | $10,000 |
NOTE: Above numbers are our estimate based on HOLX's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
Company Info
Hologic, Inc. (HOLX) had its IPO on 1990-03-01, and is trader on NASDAQ stock exchange.
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
HOLX website: https://www.hologic.com
